TY - CHAP M1 - Book, Section TI - Goodman & Gilman Year in Review New and Noteworthy FDA Regulatory Actions A1 - Murri, PharmD, MBA, Nelda A2 - Brunton, Laurence L. A2 - Hilal-Dandan, Randa A2 - Knollmann, Björn C. Y1 - 2017 N1 - T2 - Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 13e AB - In 2017 the U.S. Food and Drug Administration (FDA) approved 40 new small molecule drugs and granted 48 noteworthy biologic licenses. Among the 40 small molecules are two previously unapproved marketed drugs: calcium gluconate injection for symptomatic hypocalcemia (original approval 1941)1 and ascorbic acid injection (Ascor) for the short-term treatment of scurvy (initial approval 1947).2 SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accessbiomedicalscience.mhmedical.com/content.aspx?aid=1164576178 ER -